Skip to content

Ardelyx ARDX Deferred royalty obligation related to the sale of future royalties

Deferred royalty obligation related to the sale of future royalties at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$121.63M+0.1%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+42.1%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$407.18M-12.7%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$100M0.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$40.32M+17.5%
Mannkind logo
MannkindMNKD
$136.56M-0.6%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept ardx:DeferredRoyaltyObligationNoncurrent.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's deferred royalty obligation related to the sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's deferred royalty obligation related to the sale of future royalties?
Ardelyx (ARDX) reported deferred royalty obligation related to the sale of future royalties of $25.86M in Q1 2026.
How has Ardelyx's deferred royalty obligation related to the sale of future royalties changed year-over-year?
Ardelyx's deferred royalty obligation related to the sale of future royalties decreased by 2.5% year-over-year, from $26.52M to $25.86M.
What does deferred royalty obligation related to the sale of future royalties mean?
This represents the long-term liability associated with the sale of future royalty streams to third-party investors in exchange for upfront capital. It reflects the portion of future revenue that is contractually committed to repaying these financing arrangements. This metric is critical for understanding the company's future cash flow encumbrances and financing costs.